Bank of America Securities analyst Jason Gerberry has maintained their bullish stance on ACLX stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason Gerberry has given his Buy rating due to a combination of factors, primarily focusing on the promising data from Arcellx Inc’s iMMagine-1 study. The study results highlighted that anito cel, a BCMA CAR-T therapy, maintains a best-in-class profile with no delayed neurotoxicity and efficacy metrics that are at least comparable to its main competitor, Carvykti. This positive data strengthens the outlook for anito cel’s launch in the 4L+ multiple myeloma market in 2026, with expectations of rapid uptake among healthcare providers.
Furthermore, the safety profile of anito cel remains a significant differentiator, with low rates of severe cytokine release syndrome and ICANS, which are favorable when compared to Carvykti. Arcellx’s strategic plans to initiate further studies, such as iMMagine-4 for 1L multiple myeloma, and the positive feedback from medical experts on the sequencing of CAR-T therapies, further support the Buy rating. These elements collectively contribute to a positive long-term outlook for Arcellx Inc, justifying the price objective of $112.00.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $111.00 price target.